Publication: 3401

Publication: 3401

Daratumumab (DARA) Plus Lenalidomide, Bortezomib, and Dexamethasone (RVd) in Patients with Transplant-eligible Newly Diagnosed Multiple Myeloma (NDMM): Updated Analysis of GRIFFIN After 12-months of Maintenance Therapy (AFT-29)

URL

Google Scholar

Citation:: Blood vol 36 (Supplment 1) 45-46

Meeting Instance:: ASH 2020
Year:: 2020
Type:: Abstract
Sub type:
Funding:: AFT
Endpoint:: Primary
Analysis:: Long-Term-Followup
Data Sharing:: No-Data-Sharing
Status:: Presented/Published
Citation Status:: ppub

Note:

Methodological:: No
Biospecimen:: No
SDC:: No

Parents:: None
Children:: 3304

Program:: OGC
Primary Committee:: Myeloma
Sec. Committees:

Pharmas:: Janssen Oncology
Grants:

Corr. Author:
Authors:: Jonathan L. Kaufman Jacob Laubach Douglas W. Sborov Brandi Reeves Cesar Rodriguez Ajai Chari Rebecca Silbermann Luciano J. Costa Larry D. Anderson Jr Nitya Nathwani Nina Shah Yvonne A. Efebera Sarah A. Holstein Caitlin Costello Andrzej Jakubowiak Tanya M. Wildes Robert Z. Orlowski Kenneth H. Shain Andrew J. Cowan Yana Lutska Cynthia Haines Huiling Pei Jon Ukropec Jessica Vermeulen Thomas S. Lin Paul G. Richardson Peter M. Voorhees

Networks:: CA043, CA249, CA824, FL065, LAPS-AL002, LAPS-IL057, LAPS-MA036, LAPS-NC007, LAPS-OH007, LAPS-TX011, LAPS-TX035, LAPS-UT003, NC002, NE003, NEWMEXICO, NY021, OH008, OR013

Study: AFT-29 (GRIFFIN)
Multiple Studies, or Legacy Studies in Alliance Study:
Phases:: 2

Keywords: